Waters Corporation (WAT) - 10-K Summary for Fiscal Year Ended December 31, 2007
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Waters Corporation for the fiscal year ended December 31, 2007. Waters is a leading manufacturer of analytical instruments, operating through two primary divisions: the Waters Division (High Performance Liquid Chromatography, Ultra Performance Liquid Chromatography, and Mass Spectrometry) and the TA Division (Thermal Analysis, Rheometry, and Calorimetry). The company serves pharmaceutical, life science, industrial, academic, and government customers globally. Approximately 68% of net sales are derived from operations outside the United States.
Key Financial Metrics
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Net Sales | $1,473.0 million | $1,280.2 million | $1,158.2 million |
| Gross Profit | $841.9 million | $744.0 million | $679.9 million |
| Gross Margin | 57.2% | 58.1% | 58.7% |
| Operating Income | $348.9 million | $295.2 million | $283.2 million |
| Net Income | $268.1 million | $222.2 million | $202.0 million |
| Diluted EPS | $2.62 | $2.13 | $1.74 |
| Operating Cash Flow | $370.5 million | $263.6 million | $298.1 million |
| Total Debt | $884.2 million | $885.0 million | $885.0 million |
| Cash & Short-term Investments | $693.0 million | $514.2 million | $493.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% in 2007 compared to 2006. Growth was driven by new product introductions (ACQUITY UPLC, Synapt HDMS), increased spending by pharmaceutical customers, and the impact of acquisitions. Foreign currency translation benefited sales growth by 3%.
- Segment Performance: The Waters Division sales grew 14%, while the TA Division sales grew 27%. TA growth was significantly aided by the August 2007 acquisition of Calorimetry Sciences Corporation (CSC) and the August 2006 acquisition of Thermometric AB.
- Margin Compression: Gross profit margin decreased to 57.2% from 58.1% in 2006. This was primarily due to higher manufacturing costs associated with new products and unfavorable foreign currency impacts on costs in Ireland and the UK.
- One-Time Charges: The company recorded a $12.6 million charge in 2007 related to a transitional contribution into the Waters Employee Investment Plan following the freezing of the U.S. Pension Plans. This charge was partially offset by a $0.5 million curtailment gain.
- Acquisitions: In 2007, the company acquired CSC for $7.1 million and made a $3.5 million equity investment in Thar Instruments. In 2006, significant acquisitions included Environmental Resources Associates (ERA) and VICAM.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures in 2008 to be at similar levels to 2007. The company anticipates contributing approximately $3.5 million to $7.0 million to pension plans in 2008. No specific revenue guidance was provided in the text, but management expressed confidence in financial flexibility to fund operations, repurchases, and acquisitions.
- Stock Repurchases: The company repurchased 3.4 million shares for $200.5 million in 2007. As of December 31, 2007, $333.9 million remained authorized under the February 2007 program.
- Key Risks:
- Foreign Exchange: Approximately 68% of sales are outside the U.S., exposing the company to currency fluctuations.
- Customer Concentration: Approximately 52% of sales are to the pharmaceutical and biotechnology industries, which are subject to consolidation and spending cycles.
- Intellectual Property: Ongoing patent litigation with Agilent Technologies in Germany and France remains a contingency, though the company believes outcomes will not be material.
- Debt Service: The company has significant debt ($884.2 million) and relies on cash flow and credit facilities to service obligations and fund repurchases.
Investor Verification Checklist
- Restatement of Quarterly Data: Verify the impact of the reclassification of marketable securities from cash equivalents to short-term investments in the first three quarters of 2007 (Note 19).
- Pension Plan Changes: Confirm the details of the $12.6 million transitional contribution to the 401(k) plan and the freezing of the defined benefit pension accruals effective December 31, 2007.
- Acquisition Integration: Monitor the performance of recent acquisitions (CSC, ERA, VICAM) to ensure they meet projected revenue and earnings contributions.
- Foreign Currency Exposure: Assess the impact of a strengthening U.S. dollar on future earnings, given the 68% non-U.S. sales mix.
- Patent Litigation: Track the status of the Agilent patent litigation in Germany and France for potential future provisions.